HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Further clinical studies of trimethylpurin-6-ylammonium chloride (NSC-51095) in malignant disease with special emphasis on cancer of urinary bladder.

AuthorsR W Phillips
JournalCancer chemotherapy reports (Cancer Chemother Rep) Vol. 54 Issue 3 Pg. 181-5 (Jun 1970) ISSN: 0069-0112 [Print] United States
PMID4947750 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antimetabolites
  • Purines
  • Quaternary Ammonium Compounds
Topics
  • Adenocarcinoma (drug therapy)
  • Adult
  • Aged
  • Antimetabolites (adverse effects, therapeutic use)
  • Bronchial Neoplasms (drug therapy)
  • Carcinoma, Squamous Cell (drug therapy)
  • Carcinoma, Transitional Cell (drug therapy)
  • Clinical Trials as Topic
  • Colonic Neoplasms (drug therapy)
  • Esophageal Neoplasms (drug therapy)
  • Evaluation Studies as Topic
  • Female
  • Fibrosarcoma (drug therapy)
  • Hemangioendothelioma (drug therapy)
  • Humans
  • Intestinal Neoplasms (drug therapy)
  • Kidney Neoplasms (drug therapy)
  • Laryngeal Neoplasms (drug therapy)
  • Leiomyosarcoma (drug therapy)
  • Leukopenia (chemically induced)
  • Male
  • Malignant Carcinoid Syndrome (drug therapy)
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasms (drug therapy)
  • Purines (adverse effects, therapeutic use)
  • Quaternary Ammonium Compounds (adverse effects, therapeutic use)
  • Rhabdomyosarcoma (drug therapy)
  • Urinary Bladder Neoplasms (drug therapy)
  • Urogenital Neoplasms (drug therapy)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: